Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086472993> ?p ?o ?g. }
- W2086472993 endingPage "143" @default.
- W2086472993 startingPage "138" @default.
- W2086472993 abstract "Purpose/objectiveWhole “conventional” pelvic irradiation (up to 45–50 Gy) following hysterectomy is associated with a high rate of adverse gastro-intestinal (GI) adverse events, of which around 60% correspond to acute grade 2 toxicity. The phase II RTCMIENDOMETRE trial was designed to test the hypothesis that IMRT could reduce the incidence of grade 2 or more acute GI toxicity to less than 30% in patients irradiated post-operatively for an endometrial cancer.Materials/methodsPatients with post-operative stage Ib G3, Ic or II endometrial carcinomas with no history of chronic inflammatory bowel disease were eligible. Guidelines for volume delineation and dose prescription were detailed in the protocol. The investigators were advised to use a web-based atlas developed for the RTOG 0418 study. The dose of the vaginal and nodal PTV was 45 Gy in 25 fractions. To assess the ability of the participating centres to comply with the protocol guidelines, they were requested to complete a dummy run procedure before inclusion of their 1st patient. GI and genito-urinary (GU) toxicity were graded according to the CTCAE V 3.0 classification and were prospectively recorded every week during irradiation, as well as at time of brachytherapy insertions and during the follow-up visit at week 15 (W15). Special attention was given to note any changes to the grade of adverse events between W5 and W15.ResultsFrom May 2008 to April 2010, 49 patients from 6 centres were recruited for the trial. One patient could not be treated, one patient died of vascular stroke at W3 without toxicity, and 1 patient refused to be followed-up after treatment. Thus, 46 cases were available for analysis at W15. The distribution by stage was as follows: Ib 16.3%, Ic 64.2%, II 20.4%. Thirty six patients (75%) received an additional vaginal vault boost of 6–10 Gy delivered by HDR brachytherapy in 1 or 2 fractions. Among the 47 patients who completed IMRT, 27% (95% CI 14.5–39.7%) developed at least 1 GI grade 2 adverse event (diarrhoea in 92% of cases), which mainly occurred at W4 and W5. No event corresponding to grade 3 or above was recorded. At W15, the number of patients complaining about GI events was low: 5 patients complained about persistent grade 1 diarrhoea, and 4 patients complained about haemorrhoids. Nineteen percent (95% CI 8.9–32.6%) of patients experienced grade 2 cystitis or urinary frequency which had disappeared by W15.ConclusionIn accordance with our hypothesis, post-operative IMRT resulted in a low rate (less than 30%) of acute GI grade 2 toxicity, in patients with endometrial carcinomas. At W15, no patient demonstrated a grade 2 adverse event, and the prevalence of remaining grade 1 events was less than 20%." @default.
- W2086472993 created "2016-06-24" @default.
- W2086472993 creator A5003175013 @default.
- W2086472993 creator A5020187419 @default.
- W2086472993 creator A5026548909 @default.
- W2086472993 creator A5029737211 @default.
- W2086472993 creator A5034083299 @default.
- W2086472993 creator A5034951520 @default.
- W2086472993 creator A5054571559 @default.
- W2086472993 date "2014-04-01" @default.
- W2086472993 modified "2023-09-27" @default.
- W2086472993 title "Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: Results of the phase II RTCMIENDOMETRE French multicentre trial" @default.
- W2086472993 cites W2001512621 @default.
- W2086472993 cites W2009160418 @default.
- W2086472993 cites W2014051290 @default.
- W2086472993 cites W2014254368 @default.
- W2086472993 cites W2018308790 @default.
- W2086472993 cites W2043159106 @default.
- W2086472993 cites W2055785542 @default.
- W2086472993 cites W2061420655 @default.
- W2086472993 cites W2063700258 @default.
- W2086472993 cites W2064000324 @default.
- W2086472993 cites W2068796302 @default.
- W2086472993 cites W2087645362 @default.
- W2086472993 cites W2091867909 @default.
- W2086472993 cites W2092757756 @default.
- W2086472993 cites W2105119749 @default.
- W2086472993 cites W2110224027 @default.
- W2086472993 cites W2114222627 @default.
- W2086472993 cites W2115616149 @default.
- W2086472993 cites W2128531204 @default.
- W2086472993 cites W2136508349 @default.
- W2086472993 cites W2138261897 @default.
- W2086472993 cites W2143635078 @default.
- W2086472993 cites W2147101451 @default.
- W2086472993 cites W2155717089 @default.
- W2086472993 cites W2160707855 @default.
- W2086472993 cites W2166767010 @default.
- W2086472993 doi "https://doi.org/10.1016/j.radonc.2014.01.018" @default.
- W2086472993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24630537" @default.
- W2086472993 hasPublicationYear "2014" @default.
- W2086472993 type Work @default.
- W2086472993 sameAs 2086472993 @default.
- W2086472993 citedByCount "50" @default.
- W2086472993 countsByYear W20864729932014 @default.
- W2086472993 countsByYear W20864729932015 @default.
- W2086472993 countsByYear W20864729932016 @default.
- W2086472993 countsByYear W20864729932017 @default.
- W2086472993 countsByYear W20864729932018 @default.
- W2086472993 countsByYear W20864729932019 @default.
- W2086472993 countsByYear W20864729932020 @default.
- W2086472993 countsByYear W20864729932021 @default.
- W2086472993 countsByYear W20864729932022 @default.
- W2086472993 countsByYear W20864729932023 @default.
- W2086472993 crossrefType "journal-article" @default.
- W2086472993 hasAuthorship W2086472993A5003175013 @default.
- W2086472993 hasAuthorship W2086472993A5020187419 @default.
- W2086472993 hasAuthorship W2086472993A5026548909 @default.
- W2086472993 hasAuthorship W2086472993A5029737211 @default.
- W2086472993 hasAuthorship W2086472993A5034083299 @default.
- W2086472993 hasAuthorship W2086472993A5034951520 @default.
- W2086472993 hasAuthorship W2086472993A5054571559 @default.
- W2086472993 hasBestOaLocation W20864729931 @default.
- W2086472993 hasConcept C116263406 @default.
- W2086472993 hasConcept C121608353 @default.
- W2086472993 hasConcept C126322002 @default.
- W2086472993 hasConcept C141071460 @default.
- W2086472993 hasConcept C146357865 @default.
- W2086472993 hasConcept C151730666 @default.
- W2086472993 hasConcept C197934379 @default.
- W2086472993 hasConcept C2777088508 @default.
- W2086472993 hasConcept C2777416452 @default.
- W2086472993 hasConcept C2777793932 @default.
- W2086472993 hasConcept C29730261 @default.
- W2086472993 hasConcept C509974204 @default.
- W2086472993 hasConcept C535046627 @default.
- W2086472993 hasConcept C71924100 @default.
- W2086472993 hasConcept C86803240 @default.
- W2086472993 hasConceptScore W2086472993C116263406 @default.
- W2086472993 hasConceptScore W2086472993C121608353 @default.
- W2086472993 hasConceptScore W2086472993C126322002 @default.
- W2086472993 hasConceptScore W2086472993C141071460 @default.
- W2086472993 hasConceptScore W2086472993C146357865 @default.
- W2086472993 hasConceptScore W2086472993C151730666 @default.
- W2086472993 hasConceptScore W2086472993C197934379 @default.
- W2086472993 hasConceptScore W2086472993C2777088508 @default.
- W2086472993 hasConceptScore W2086472993C2777416452 @default.
- W2086472993 hasConceptScore W2086472993C2777793932 @default.
- W2086472993 hasConceptScore W2086472993C29730261 @default.
- W2086472993 hasConceptScore W2086472993C509974204 @default.
- W2086472993 hasConceptScore W2086472993C535046627 @default.
- W2086472993 hasConceptScore W2086472993C71924100 @default.
- W2086472993 hasConceptScore W2086472993C86803240 @default.
- W2086472993 hasIssue "1" @default.
- W2086472993 hasLocation W20864729931 @default.
- W2086472993 hasLocation W20864729932 @default.
- W2086472993 hasOpenAccess W2086472993 @default.
- W2086472993 hasPrimaryLocation W20864729931 @default.